India’s Tata Institute develops tablet for cancer recurrence prevention

Preview

来源: Pharmaceutical Technology

The pro-oxidant tablet has shown a 30% effectiveness in preventing cancer. White Bear studio / Shutterstock.com.

India’s Tata Institute of Fundamental Research (TIFR) has announced the development of a new pro-oxidant tablet, combining resveratrol and copper (R+Cu), that has the potential to prevent the recurrence of cancer.

More than a decade of research at the Tata Memorial Centre has resulted in the creation of this tablet which will be priced at around Rs100 ($1.2), Indian media publication NDTV has reported.

The institute’s findings suggest that cancer cell remnants, known as cell-free chromatin particles (cfChPs), can induce cancer in healthy cells, leading to new tumour formation.

The R+Cu tablet, when ingested, produces oxygen radicals within the stomach.

These radicals are rapidly absorbed into the bloodstream, where they target and destroy cfChPs, hindering the process of metastasis—the spread of cancer cells to other body parts.

See Also:EMA awards double validation for Daiichi Sankyo and AstraZeneca’s cancer ADC

Preview

来源: Pharmaceutical Technology

Memorial Sloan Kettering Cancer Center in artificial intelligence: theme innovation strategy

Preview

来源: Pharmaceutical Technology

The tablet also reduces the toxicity associated with chemotherapy and diminishes the overall side effects of cancer treatment by around 50%.

It has shown 30% effectiveness in preventing cancer.

Its potential extends to the treatment of cancers including pancreatic, oral and lung.

Tata Memorial Hospital senior cancer surgeon Dr Rajendra Badve stated: “Tata doctors were working on this tablet for almost a decade.

“The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied to FSSAI to approve this tablet.

“This tablet will be available everywhere for just Rs100.”

The institute plans to make the tablet available from June/July 2024 for cancer patients following approval from the Indian regulator.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。